Last updated on July 2016

Type 2 Diabetes Mellitus with Heart Disease


Brief description of study

Type 2 Diabetes Mellitus with Heart Disease

Detailed Study Description

"THE VERTIS CV STUDY" Type 2 Diabetes Mellitus and Established Vascular Disease

Merck and Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpoints, Showing Significant A1C Reductions in Patients with Type 2 Diabetes http://www.mercknewsroom.com/news-release/corporate-news/merck-and-pfizer-announce-two-pivotal-phase-3-studies-ertugliflozin-inve

Clinical Study Identifier: TX144439

Contact Investigators or Research Sites near you

Start Over

Richard Menzies

Virginia Research Center
Midlothian, VA USA
  Connect »